MX343907B - Complejos de lipoproteina y fabricacion y usos de los mismos. - Google Patents
Complejos de lipoproteina y fabricacion y usos de los mismos.Info
- Publication number
- MX343907B MX343907B MX2013009083A MX2013009083A MX343907B MX 343907 B MX343907 B MX 343907B MX 2013009083 A MX2013009083 A MX 2013009083A MX 2013009083 A MX2013009083 A MX 2013009083A MX 343907 B MX343907 B MX 343907B
- Authority
- MX
- Mexico
- Prior art keywords
- lipoprotein complexes
- manufacturing
- lipoprotein
- apolipoproteins
- complexes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un método para preparar complejos de lipoproteína, caracterizado porque comprende: (a) enfriar una suspensión inicial que comprende un componente de lípido y un componente de proteína desde una temperatura en una primera escala de temperatura hasta una temperatura en segunda escala de temperatura, en donde dicha primera escala de temperatura incluye temperaturas de no menos de 10 grados abajo y no más de 15 grados arriba de la temperatura de transición de dicho componente de proteína, y en donde (i) el componente de lípido consiste esencialmente de partículas de lípidos formadas mediante homogeneización; y (ii) el componente de proteína consiste esencialmente en péptidos de unión a lípido y/o proteínas de unión a lípido que no han sido sometidas a homogeneización y, opcionalmente, un lípido en una cantidad que es 10% o menos en peso del contenido total de lípido en la suspensión inicial ; (b) calentar la suspensión enfriada de (a) desde una temperatura de dicha segunda escala de temperatura hasta una temperatura de dicha primera escala de temperatura; (c) enfriar dicha suspensión calentada de (b) desde una temperatura de dicha primera escala de temperatura hasta una temperatura de dicha segunda escala de temperatura; y (d) repetir los pasos (b) y (c) hasta que por lo menos 80% del componente de proteína esté incorporado en complejos de lipoproteína, formado de esta manera complejos de lipoproteína.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440371P | 2011-02-07 | 2011-02-07 | |
| US201161452630P | 2011-03-14 | 2011-03-14 | |
| US201161487263P | 2011-05-17 | 2011-05-17 | |
| PCT/US2012/024020 WO2012109162A1 (en) | 2011-02-07 | 2012-02-06 | Lipoprotein complexes and manufacturing and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013009083A MX2013009083A (es) | 2014-02-03 |
| MX343907B true MX343907B (es) | 2016-11-28 |
Family
ID=45592833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009083A MX343907B (es) | 2011-02-07 | 2012-02-06 | Complejos de lipoproteina y fabricacion y usos de los mismos. |
| MX2016011834A MX355159B (es) | 2011-02-07 | 2013-08-06 | Complejos de lipoproteina y fabricacion y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011834A MX355159B (es) | 2011-02-07 | 2013-08-06 | Complejos de lipoproteina y fabricacion y usos de los mismos. |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US20120232005A1 (es) |
| EP (4) | EP4400511A3 (es) |
| JP (5) | JP6219170B2 (es) |
| KR (1) | KR20140053848A (es) |
| CN (4) | CN103443123B (es) |
| AU (1) | AU2012214672B2 (es) |
| CA (1) | CA2826158A1 (es) |
| CY (2) | CY1121317T1 (es) |
| DK (3) | DK3466969T3 (es) |
| ES (3) | ES2994009T3 (es) |
| HK (1) | HK1198834A1 (es) |
| HR (2) | HRP20190072T1 (es) |
| HU (2) | HUE042314T2 (es) |
| IL (1) | IL227634B (es) |
| IN (1) | IN2013DN07828A (es) |
| LT (2) | LT2673296T (es) |
| MX (2) | MX343907B (es) |
| PH (2) | PH12013501644A1 (es) |
| PL (2) | PL2673296T3 (es) |
| PT (2) | PT2767546T (es) |
| RS (2) | RS58275B1 (es) |
| RU (2) | RU2017126088A (es) |
| SG (2) | SG192693A1 (es) |
| SI (2) | SI2673296T1 (es) |
| SM (2) | SMT201900194T1 (es) |
| TW (2) | TW201240671A (es) |
| WO (1) | WO2012109162A1 (es) |
| ZA (1) | ZA201305628B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| DK3178481T3 (en) | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| JP6219170B2 (ja) | 2011-02-07 | 2017-10-25 | セレニス セラピューティクス ホールディング エスアー | リポタンパク質複合体ならびにその製造および使用 |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| JP2016509068A (ja) * | 2013-02-28 | 2016-03-24 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| SG10201804887YA (en) | 2013-03-15 | 2018-07-30 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| CA2920391C (en) * | 2013-08-08 | 2023-03-28 | Csl Limited | Contaminant removal method |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| CN106488987A (zh) | 2014-05-02 | 2017-03-08 | 塞勒尼斯医疗控股公司 | Hdl疗法标志物 |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| KR101671580B1 (ko) * | 2014-08-26 | 2016-11-02 | 영남대학교 산학협력단 | 미녹시딜 수용액 제조방법 |
| WO2016123365A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| US11219673B2 (en) | 2015-03-25 | 2022-01-11 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US11642419B2 (en) | 2015-03-25 | 2023-05-09 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
| CA3032229A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
| WO2018029505A1 (en) | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| WO2018136866A1 (en) * | 2017-01-23 | 2018-07-26 | Hdl Therapeutics, Inc. | Methods for treating cholesterol-related diseases |
| ES2681124B1 (es) | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
| ES2984286T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| EP3668600B1 (en) * | 2017-08-10 | 2024-05-15 | Abionyx Pharma SA | Cargomers |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| MX2020013633A (es) * | 2018-07-03 | 2021-03-25 | Bristol Myers Squibb Co | Metodos para producir proteinas recombinantes. |
| JP2020138941A (ja) * | 2019-02-28 | 2020-09-03 | 国立研究開発法人理化学研究所 | バイセル及びその利用 |
| JP2023502496A (ja) | 2019-11-20 | 2023-01-24 | アルカヘスト，インコーポレイテッド | 肝臓再生に使用するための血漿画分 |
| US11484551B2 (en) | 2019-11-20 | 2022-11-01 | Alkahest, Inc. | Method of treating liver failure with plasma fraction IV-4 |
| US11969280B2 (en) | 2020-01-07 | 2024-04-30 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| JP2023522889A (ja) | 2020-04-16 | 2023-06-01 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法 |
| US20240000948A1 (en) | 2020-10-01 | 2024-01-04 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| US20240050522A1 (en) * | 2020-12-11 | 2024-02-15 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES |
| WO2022150631A1 (en) * | 2021-01-08 | 2022-07-14 | Hdl Therapeutics, Inc | Systems and methods for reducing low attenuation plaque and/or plaque burden in patients |
| KR20240018430A (ko) | 2021-04-15 | 2024-02-13 | 아비오닉스 파마 에스에이 | 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용 |
| AU2022275694A1 (en) * | 2021-05-19 | 2023-11-16 | Alkahest, Inc. | Blood plasma fractions for use in liver regeneration |
| US20230289963A1 (en) * | 2022-03-10 | 2023-09-14 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| KR20240167701A (ko) | 2022-04-06 | 2024-11-27 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법 |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| IL317448A (en) | 2022-06-10 | 2025-02-01 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins |
| IL317446A (en) | 2022-06-10 | 2025-02-01 | Abionyx Pharma Sa | Methods for treating acute conditions using complexes based on lipid-binding proteins |
| KR20250035547A (ko) | 2022-06-28 | 2025-03-12 | 아비오닉스 파마 에스에이 | 스핑고미엘린의 합성을 위한 화합물 및 공정 |
| KR20240009061A (ko) * | 2022-07-13 | 2024-01-22 | (재)씨젠의료재단 | 혈청 내 다중 아포지단백질의 직접정량 방법 |
| WO2024150064A1 (en) | 2023-01-13 | 2024-07-18 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| AU587989B2 (en) | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
| EP0209543A4 (en) | 1984-12-31 | 1989-07-11 | Internat Genetic Engineering I | FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE. |
| GB8625435D0 (en) | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| IT1229996B (it) | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| WO1993000443A1 (en) | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| AU5457294A (en) | 1992-10-29 | 1994-05-24 | Board Of Regents, The University Of Texas System | Adenovirus-mediated ldl receptor gene transfer and targeting |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
| US5643757A (en) | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
| WO1995025749A2 (en) | 1994-03-22 | 1995-09-28 | Research Corporation Technologies, Inc. | Eating suppressant peptides |
| IL109558A (en) | 1994-05-04 | 2004-08-31 | Yissum Res Dev Co | DNA structures Derived from the SV40 virus that include DNA sequences External |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US6258596B1 (en) | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
| FR2734568B1 (fr) | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AU784506B2 (en) | 1999-08-25 | 2006-04-13 | Immunex Corporation | Compositions and methods for improved cell culture |
| US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US20030224415A1 (en) | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
| KR100545945B1 (ko) | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| AU7161401A (en) | 2000-07-03 | 2002-01-14 | Gala Design Inc | Host cells containing multiple integrating vectors |
| US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| EP1335938B1 (en) * | 2000-11-10 | 2010-09-22 | F. Hoffmann-La Roche Ltd. | Apolipoprotein construct |
| CA2429473C (en) | 2000-11-20 | 2011-02-15 | The Board Of Trustees Of The University Of Illinois | Membrane scaffold proteins |
| EP1366062B1 (en) | 2001-02-23 | 2011-07-27 | Immunex Corporation | Efficient recovery of correctly refolded proteins |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| CA2457840C (en) | 2001-08-20 | 2011-10-11 | Zlb Bioplasma Ag | Hdl for the treatment of stroke and other ischemic conditions |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| AU2003239489A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| BR0313069A (pt) * | 2002-07-30 | 2007-07-17 | Esperion Therapeutics Inc | métodos de tratamento de um ser humano sofrendo de um distúrbio associado com dislipidemia e de tratamento de um paciente sofrendo de uma infecção, composição farmacêutica, complexo de lipìdeo-proteìna apoa-i animal não-humana, e, método de administração da composição |
| JP2006508126A (ja) * | 2002-11-06 | 2006-03-09 | アザヤ セラピューティクス インコーポレイティッド | 薬学的製剤のタンパク質安定化されたリポソーム製剤 |
| EP2368565B1 (en) * | 2003-07-03 | 2015-06-24 | HDL Therapeutics, Inc. | Enrichment of pre-beta high density lipoproteins |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US20060030525A1 (en) | 2004-07-23 | 2006-02-09 | Xencor, Inc. | Apolipoprotein A-I derivatives with altered immunogenicity |
| US8206750B2 (en) * | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| CN101253195A (zh) * | 2005-08-26 | 2008-08-27 | 科莱尼斯医疗控股公司 | 用于在乳酸菌中制备载脂蛋白基因产物的组合物和方法 |
| US8541236B2 (en) * | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| WO2008104890A2 (en) * | 2007-02-28 | 2008-09-04 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein |
| WO2008141230A1 (en) * | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
| US8436152B2 (en) | 2007-08-17 | 2013-05-07 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1 |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| CA2703962A1 (en) * | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| BRPI0915093A2 (pt) * | 2008-06-13 | 2015-10-27 | Proyecto Biomedicina Cima Sl | conjugados para a administração de compostos biologicamente ativos |
| WO2010093918A1 (en) | 2009-02-16 | 2010-08-19 | Cerenis Therapeutics Sa | Apolipoprotein a-i mimics |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| JP6219170B2 (ja) | 2011-02-07 | 2017-10-25 | セレニス セラピューティクス ホールディング エスアー | リポタンパク質複合体ならびにその製造および使用 |
| CA2830664A1 (en) * | 2011-03-25 | 2012-10-04 | The Trustees Of Columbia University In The City Of New York | Pegylated human hdl particle and process for production thereof |
-
2012
- 2012-02-06 JP JP2013552722A patent/JP6219170B2/ja active Active
- 2012-02-06 KR KR1020137023430A patent/KR20140053848A/ko not_active Application Discontinuation
- 2012-02-06 SI SI201231514T patent/SI2673296T1/sl unknown
- 2012-02-06 RU RU2017126088A patent/RU2017126088A/ru not_active Application Discontinuation
- 2012-02-06 MX MX2013009083A patent/MX343907B/es active IP Right Grant
- 2012-02-06 CN CN201280015257.3A patent/CN103443123B/zh active Active
- 2012-02-06 ES ES18195447T patent/ES2994009T3/es active Active
- 2012-02-06 DK DK18195447.0T patent/DK3466969T3/da active
- 2012-02-06 EP EP24174300.4A patent/EP4400511A3/en active Pending
- 2012-02-06 AU AU2012214672A patent/AU2012214672B2/en active Active
- 2012-02-06 LT LTEP12703947.7T patent/LT2673296T/lt unknown
- 2012-02-06 SI SI201231508T patent/SI2767546T1/sl unknown
- 2012-02-06 DK DK14150349.0T patent/DK2767546T3/en active
- 2012-02-06 ES ES14150349T patent/ES2716349T3/es active Active
- 2012-02-06 US US13/367,237 patent/US20120232005A1/en not_active Abandoned
- 2012-02-06 CN CN201710493059.2A patent/CN107337728B/zh active Active
- 2012-02-06 HU HUE12703947A patent/HUE042314T2/hu unknown
- 2012-02-06 CN CN201510717344.9A patent/CN105294859A/zh active Pending
- 2012-02-06 CA CA2826158A patent/CA2826158A1/en active Pending
- 2012-02-06 PT PT14150349T patent/PT2767546T/pt unknown
- 2012-02-06 WO PCT/US2012/024020 patent/WO2012109162A1/en active Application Filing
- 2012-02-06 EP EP12703947.7A patent/EP2673296B1/en active Active
- 2012-02-06 SM SM20190194T patent/SMT201900194T1/it unknown
- 2012-02-06 ES ES12703947T patent/ES2717455T3/es active Active
- 2012-02-06 HU HUE14150349A patent/HUE041797T2/hu unknown
- 2012-02-06 EP EP18195447.0A patent/EP3466969B1/en active Active
- 2012-02-06 EP EP14150349.0A patent/EP2767546B1/en active Active
- 2012-02-06 SM SM20190045T patent/SMT201900045T1/it unknown
- 2012-02-06 PH PH1/2013/501644A patent/PH12013501644A1/en unknown
- 2012-02-06 RS RS20190093A patent/RS58275B1/sr unknown
- 2012-02-06 PL PL12703947T patent/PL2673296T3/pl unknown
- 2012-02-06 RU RU2013139066A patent/RU2627173C2/ru not_active IP Right Cessation
- 2012-02-06 DK DK12703947.7T patent/DK2673296T3/en active
- 2012-02-06 IN IN7828DEN2013 patent/IN2013DN07828A/en unknown
- 2012-02-06 PT PT12703947T patent/PT2673296T/pt unknown
- 2012-02-06 LT LTEP14150349.0T patent/LT2767546T/lt unknown
- 2012-02-06 SG SG2013060512A patent/SG192693A1/en unknown
- 2012-02-06 RS RS20190073A patent/RS58243B1/sr unknown
- 2012-02-06 PL PL14150349T patent/PL2767546T3/pl unknown
- 2012-02-06 CN CN201510711086.3A patent/CN105288589A/zh active Pending
- 2012-02-06 SG SG10201801372YA patent/SG10201801372YA/en unknown
- 2012-02-07 TW TW101103979A patent/TW201240671A/zh unknown
- 2012-02-07 TW TW106109180A patent/TW201737935A/zh unknown
-
2013
- 2013-07-24 ZA ZA2013/05628A patent/ZA201305628B/en unknown
- 2013-07-24 IL IL227634A patent/IL227634B/en active IP Right Grant
- 2013-08-06 MX MX2016011834A patent/MX355159B/es unknown
- 2013-12-11 US US14/103,686 patent/US9187551B2/en active Active
-
2014
- 2014-07-17 US US14/334,519 patent/US10328119B2/en active Active
- 2014-12-08 HK HK14112302.2A patent/HK1198834A1/xx unknown
-
2015
- 2015-10-15 US US14/884,115 patent/US10322163B2/en active Active
-
2016
- 2016-01-27 PH PH12016500191A patent/PH12016500191A1/en unknown
-
2017
- 2017-09-27 JP JP2017186171A patent/JP6720126B2/ja active Active
-
2019
- 2019-01-10 HR HRP20190072TT patent/HRP20190072T1/hr unknown
- 2019-01-17 CY CY20191100061T patent/CY1121317T1/el unknown
- 2019-01-21 HR HRP20190138TT patent/HRP20190138T1/hr unknown
- 2019-01-21 CY CY20191100078T patent/CY1121318T1/el unknown
- 2019-04-29 US US16/397,944 patent/US11376309B2/en active Active
-
2020
- 2020-06-17 JP JP2020104518A patent/JP7009559B2/ja active Active
-
2022
- 2022-01-12 JP JP2022003351A patent/JP2022050603A/ja active Pending
- 2022-05-27 US US17/826,659 patent/US20220362336A1/en active Pending
-
2023
- 2023-08-04 US US18/365,328 patent/US11998587B2/en active Active
- 2023-08-04 US US18/365,367 patent/US11969456B2/en active Active
-
2024
- 2024-09-03 JP JP2024151092A patent/JP2024170492A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500191A1 (en) | Lipoprotein complexes and manufacturing and uses thereof | |
| JO3199B1 (ar) | مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها | |
| UA115887C2 (uk) | АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ | |
| MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
| EA201170465A1 (ru) | Способы лечения прогрессирующего множественного склероза | |
| MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| PH12014501595A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| PH12014500460A1 (en) | Substituted annellated pyrimidine and the use thereof | |
| PH12014502496B1 (en) | Bicyclically substituted uracils and the use thereof | |
| MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| PH12016500065A1 (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof | |
| MX362271B (es) | Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso. | |
| BR112013022052A2 (pt) | ligantes antagonísticos de dr3 | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX355972B (es) | Canfenos arilados novedosos, procesos para su preparacion y usos. | |
| PH12016500608A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| MX2013002261A (es) | N-fenetiltriazolonacetamidas sustituidas y su uso. | |
| UA114486C2 (uk) | Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності | |
| WO2013074816A3 (en) | Novel inhibitors of nox1 | |
| MX2013012967A (es) | Composicion de miel con l-alanil-l-glutamina. | |
| PH12014500577A1 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| PH12015500322A1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| TN2013000243A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |